The post GENUS BARIUM FLAVORSELECT BERRY PACKET 5ML 24/BX appeared first on SpectrumXray.

The post GENUS BARIUM FLAVORSELECT ORANGE PACKET 5ML 24/BX appeared first on SpectrumXray.

The post GENUS BARIUM FLAVORSELECT BANANA PACKET 5ML 24/BX appeared first on SpectrumXray.

• Echocardiography Lumason is indicated for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
• Ultrasonography of the Liver: Lumason is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions.
• Ultrasonography of the Urinary Tract: Lumason is indicated for use in ultrasonography of the urinary tract in pediatric patients for the evaluation of suspected or known vesicoureteral reflux.

The post BRACCO LUMASON 25MG VIAL & SPIKE 20/BX appeared first on SpectrumXray.

• Each kit contains one Lumason vial of 25 mg lipid-type A lyophilized powder with headspace fill of 60.7 mg of sulfur hexafluoride, one prefilled-syringe containing 5 mL of Sodium Chloride 0.9% Injection and one Mini-Spike

The post BRACCO LUMASON INJECTION KIT 25MG 5/BX appeared first on SpectrumXray.

• VueWay is a gadolinium-based contrast agent indicated in adult and pediatric patients aged 2 years and older for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in:

? the central nervous system (brain, spine, and associated tissues),
? the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).

The post BRACCO VUEWAY 10ML VIAL 10/BX 703042 appeared first on SpectrumXray.

ProHance (Gadoteridol) Injection, 279.3 mg/mL provides macrocyclic GBCA stability, along with proven efficacy. The TRUTH study showed no significant difference in detection and characterization of central nervous system (CNS) lesions with ProHance^® (Gadoteridol) when compared to Gadavist^®. In addition, no difference was found by any reader for any of the 5 qualitative image evaluation endpoints:³

• Global diagnostic preference
• Lesion border delineation
• Definition of disease extent
• Visualization of lesion internal morphology
• Lesion contrast enhancement

ProHance provided improved delineation and enhancement of primary and secondary neoplastic lesions of the brain and spine in children.⁴ In a multicenter clinical trial of 103 children, 60% of scans were enhanced, and 30-95% of scans resulted in additional diagnostic information.¹

The post BRACCO PROHANCE 17ML PFS 5/BOX appeared first on SpectrumXray.

The post BRACCO PROHANCE 10ML PREFS 5/BOX appeared first on SpectrumXray.

The post CLARISCAN INJECTION 15mL 0.5mm appeared first on SpectrumXray.

• Clariscan 0.5 mmol/mL is a sterile, clear, colorless to yellow, aqueous solution for intravenous injection containing 376.9 mg/mL gadoterate meglumine.
• Glass vial: Aseptically draw up the contrast medium into a disposable syringe and use immediately.
• To ensure complete injection of Clariscan, the injection may be followed by normal saline flush. Contrast MRI can begin immediately following Clariscan injection.
• Visually inspect Clariscan for particulate matter prior to administration. Do not use the solution if particulate matter is present or if the container appears damaged. Clariscan should be a clear, colorless to yellow solution.
• Do not mix with other drugs or parenteral nutrition.
• Discard any unused portions of the drug.

The post Clariscan Injection 10mL 0.5mm – Precise MRI Contrast Enhancement for Accurate Diagnostics appeared first on SpectrumXray.